About FDA
Number of highest risk product domestic inspections in the month resulting in a category of classifications called OTHER
Dictionary: The number of highest-risk product inspections where one of the following four outcomes occurred. 1. Referred to State for Follow-Up: the findings of the inspection were such that there is no federal jurisdiction over the apparent violation in question or it is determined that State action is the most efficient method of obtaining the establishment’s compliance with Federal laws, regulations or administrative requirements. 2. Referred to Center: the Establishment Inspection Report has been referred to the appropriate Center for a final inspection district decision. 3. Not Yet Completed by Investigator: the inspection has been completed but the investigator has not yet reported [into the database] what district decision will be recommended. 4. Not Yet Endorsed by Investigations: the investigator’s recommendation is that the district decision should be OAI but this recommendation has not yet been endorsed (reviewed and approved) by the investigator’s supervisor
Fiscal Year - 2012
| Time | Target | Number Classified as Other |
|---|---|---|
| Oct 2011 | N/A | 10 |
| Nov 2011 | N/A | 9 |
| Dec 2011 | N/A | 12 |
| Jan 2012 | N/A | 9 |
| Feb 2012 | N/A | 11 |
| Mar 2012 | N/A | 11 |
| Apr 2012 | N/A | 8 |
| May 2012 | N/A | 10 |
| Jun 2012 | N/A | 13 |
| Jul 2012 | N/A | 7 |
| Aug 2012 | N/A | 11 |
| Sep 2012 | N/A | 16 |
FY 2012 Total: 127
Percent of highest risk domestic inspections in the month resulting in a classification of Other
Fiscal Year - 2012
| Time | Target | Percent Classified as Other |
|---|---|---|
| Oct 2011 | N/A | 1 |
| Nov 2011 | N/A | 1 |
| Dec 2011 | N/A | 1 |
| Jan 2012 | N/A | 1 |
| Feb 2012 | N/A | 1 |
| Mar 2012 | N/A | 1 |
| Apr 2012 | N/A | 1 |
| May 2012 | N/A | 1 |
| Jun 2012 | N/A | 1 |
| Jul 2012 | N/A | 1 |
| Aug 2012 | N/A | 1 |
| Sep 2012 | N/A | 2 |
Glossary
Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.







